Incyte (NASDAQ:INCY) Stock Rating Lowered by Guggenheim
Guggenheim lowered shares of Incyte (NASDAQ:INCY – Free Report) from a buy rating to a neutral rating in a report issued on Tuesday, Marketbeat Ratings reports. They currently have $92.00 price objective on the biopharmaceutical company’s stock. Several other brokerages have also recently issued reports on INCY. Citigroup reduced their price target on shares of […]
Guggenheim lowered shares of Incyte (NASDAQ:INCY – Free Report) from a buy rating to a neutral rating in a report issued on Tuesday, Marketbeat Ratings reports. They currently have $92.00 price objective on the biopharmaceutical company’s stock. Several other brokerages have also recently issued reports on INCY. Citigroup reduced their price target on shares of […]
